News articles featuring quotes from Real Endpoints

<>

January 31, 2018

In Vivo

Biopharma 2018: Is there still a place for pharma in the new health care economy?

by William Looney

Biopharma is not moving as quickly in 2018 as its counterparts in adjacent industry segments, and is confronting a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

read full article >

December 1, 2017

Scrip

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

by Emily Hayes

Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.

read full article >

November 20, 2017

In Vivo

Proving the Value of Value-Based Deals

by Ed Silverman

As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.

read full article >

July 18, 2017

In Vivo

The Value Lab: Moving Value-Based Health Care from Theory to Practice

by Roger Longman

A new, structured approach to bringing value-based reimbursement models into the mainstream is outlined, thus transforming reimbursement and fueling the shift from volume to value.

read full article >

July 7, 2017

Bloomberg

Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses

by Doni Bloomfield

Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.

read full article >

May 16, 2017

BioCentury

Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals

by Roger Longman

Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.

read full article >